Global Powerhouses Join Forces: A New Era for Rare Blood Disease Treatment
Ionis Pharmaceuticals and Ono Pharmaceutical have partnered to target polycythemia vera (PV), a rare blood disorder. Sapablursen, an RNA-targeted therapy, is central to their endeavor, having completed a Phase 2 trial with FDA Fast Track and orphan drug designations. The agreement includes
